Skip to content
Trending storyDeveloping

Drug sponsors keep ultimate responsibility as development shifts to outside partners

1 article1 sourcesince Nov 5Last article 2h ago ·

Overview

AISummary of 1 article

An article argues that drug development is increasingly run as a network of specialist partners, while sponsors remain fully responsible for the work under ICH GCP E6(R3).

It cites Mithril Medicine, which reportedly runs its programs with one employee coordinating 11 external labs using Claude, and Formation Bio, which has a $600 million fund aiming for 10 to 15 clinical-stage programs. The article also points to FDA and EMA actions against contract research organizations Synchron, Panexcell and Synapse Labs, arguing that one provider's failure can affect many sponsors.

Written by AI from the articles below · updated Nov 5, 3:20 AM ET

Check the sources:

Latest developmentNov 5, 2:03 AM ET
Drug development is modular, but sponsors keep ultimate responsibility

Article timeline

The articles in this story. Times are ET.

Nov 5
  1. LIFE AIX
    Drug development is modular, but sponsors keep ultimate responsibility

    AIThe article argues that drug development is increasingly organized as a network of specialist partners, while sponsors retain ultimate responsibility under ICH GCP E6(R3). It cites Mithril Medicine's one-employee model coordinating 11 external labs with Claude, and Formation Bio's $600 million fund aiming for 10 to 15 clinical-stage programs. It also cites FDA and EMA actions against CROs Synchron, Panexcell and Synapse Labs, showing how one provider's failure can reach many sponsors.

Heat Trend

Not enough continuous observations to show a trend yet.